Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Frequently asked questions
What sector does Kyntra Bio, Inc. (KYNB) operate in?
Kyntra Bio, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kyntra Bio, Inc. (KYNB) current stock price?
As of the latest data, Kyntra Bio, Inc. stock price is $4.50, with a previous close of $4.50.
What is Kyntra Bio, Inc. (KYNB) current market capitalization?
Kyntra Bio, Inc. market cap is approximately 18.22 million.
What is Kyntra Bio, Inc. (KYNB) Earnings Per Share (EPS)?
The trailing EPS is -$7.51, and the forward EPS is -$14.23.
What is Kyntra Bio, Inc. (KYNB) EBITDA?
Kyntra Bio, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -49.49 million.
Does Kyntra Bio, Inc. (KYNB) pay dividends?
No. Kyntra Bio, Inc. does not pay a dividend.
How did Kyntra Bio, Inc. (KYNB) perform in its most recent earnings report?
In the last report (June 30, 2026), Kyntra Bio, Inc. posted an EPS surprise of -47.17% and a revenue surprise of -173.47%.
When is Kyntra Bio, Inc. (KYNB) next earnings report?
Kyntra Bio, Inc. is expected to release its next earnings report on September 30, 2026.
What is Kyntra Bio, Inc. (KYNB) beta (volatility) score?
Kyntra Bio, Inc. has a beta of 1.064, meaning its volatility is roughly in line with the market.
